<- Go Home
Next Science Limited
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Market Cap
AUD 25.8M
Volume
152.4K
Cash and Equivalents
AUD 1.7M
EBITDA
-AUD 9.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 18.4M
Profit Margin
80.83%
52 Week High
AUD 0.20
52 Week Low
AUD 0.04
Dividend
N/A
Price / Book Value
7.51
Price / Earnings
-2.44
Price / Tangible Book Value
9.88
Enterprise Value
AUD 26.7M
Enterprise Value / EBITDA
-2.81
Operating Income
-AUD 10.2M
Return on Equity
130.18%
Return on Assets
-47.12
Cash and Short Term Investments
AUD 1.7M
Debt
AUD 2.5M
Equity
AUD 3.4M
Revenue
AUD 22.8M
Unlevered FCF
-AUD 5.0M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium